The Patent Trial and Appeal Board erroneously construed the term “aseptic” in an inter partes review (IPR) of a patent for a method of aseptically bottling sterilized food, the U.S. Court of Appeals for the Federal Circuit has held. The Board erred in construing the term as incorporating “any applicable United States FDA standard” rather than only FDA regulations governing “aseptic packaging.” The court vacated and remanded a Board decision finding that three claims of the patent were not obvious in light of prior art (Nestle USA, Inc. v. Steuben Foods, Inc., May 9, 2017, Hughes, T.).

A full summary of this case has been published on Kluwer IP Law



Kluwer IP Law
This page as PDF